Watershed Asset Management L.L.C. Buys 108 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Watershed Asset Management L.L.C. boosted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 9.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,275 shares of the biotechnology company’s stock after acquiring an additional 108 shares during the period. Watershed Asset Management L.L.C.’s holdings in United Therapeutics were worth $280,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in UTHR. GAMMA Investing LLC bought a new stake in United Therapeutics in the fourth quarter worth about $43,000. C M Bidwell & Associates Ltd. bought a new stake in United Therapeutics in the third quarter worth about $91,000. Ronald Blue Trust Inc. increased its stake in shares of United Therapeutics by 155.9% in the third quarter. Ronald Blue Trust Inc. now owns 458 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 279 shares in the last quarter. Blue Trust Inc. increased its stake in shares of United Therapeutics by 10.0% in the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 46 shares in the last quarter. Finally, CWM LLC increased its stake in shares of United Therapeutics by 45.7% in the fourth quarter. CWM LLC now owns 670 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 210 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on UTHR. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $213.00 to $215.00 in a research note on Monday, February 12th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $294.25.

United Therapeutics Price Performance

NASDAQ:UTHR traded up $0.41 during mid-day trading on Tuesday, hitting $234.47. 521,396 shares of the stock traded hands, compared to its average volume of 435,510. The business’s 50-day moving average price is $232.48 and its 200 day moving average price is $228.69. The company has a market cap of $11.03 billion, a PE ratio of 11.82 and a beta of 0.52. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $261.54. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, beating the consensus estimate of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company had revenue of $614.70 million during the quarter, compared to analysts’ expectations of $575.01 million. During the same quarter in the previous year, the company earned $2.67 earnings per share. United Therapeutics’s revenue for the quarter was up 25.1% on a year-over-year basis. On average, analysts expect that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $236.47, for a total value of $851,292.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,741.10. The transaction was disclosed in a filing with the SEC, which is available through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $248.33, for a total value of $3,724,950.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $32,282.90. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $236.47, for a total transaction of $851,292.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,741.10. The disclosure for this sale can be found here. Insiders sold a total of 133,390 shares of company stock valued at $31,379,925 in the last quarter. Corporate insiders own 12.50% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.